CRISPR Therapy 2017

Global Genome Editing Market
The global genome editing market in 2016 is estimated at USD 2.84 Billion and forecasted to
grow at a CAGR of 14.3% to reach USD 5.54 Billion by 2021. Genome editing therapies correct disease-causing mutations and are usually categorized by type of technology used.
CRISPR Therapy
“CRISPR” is an acronym of Clustered Regularly Interspaced Short Palindromic Repeats.
CRISPR technology is based on a bacterial defense mechanism, composed of two molecules
structure that easily alters DNA sequences, modifies gene function to correct genetic defects
causing existing diseases, and also help prevent future diseases. CRISPR therapy has dominated
the global genome editing market in 2016 and predicted to achieve highest CAGR growth throughout

CRISPR/Cas9 is patented by nonprofit Broad institute of Harvard and MIT. Cas9 is a CRISPR
associated enzyme named “endonuclease”, nicknamed as “molecular scissors” which is capable
of cut and edit, or correct, disease-associated abnormality in a genomic DNA by simple
structured programming. CRISPR/Cas9 is the most cost effective method and is considered to be
the most accurate compared to other therapy in gene editing segment.
Exclusive usage license of CRISPR/Cas9 technology were granted to three for-profit companies
namely CRISPR Therapeutics, Editas Medicine and Intellia Therapeutics. Major research
activity with CRISPR/Cas9 technology is centered on Cancer immunotherapy, HIV, Hepatitis B,
Obesity and metabolism, Tissue regeneration, Malaria and insect borne diseases, and many more
therapies to treat orphan or ultra-orphan health conditions. In 2016, NIH advisory committee,
first time approved the use of CRISPR/Cas9 gene editing technology in a cancer therapy.

Majority of CRISPR/cas9 therapies under research are in pre-clinical stage and not even entered
in clinical trials and will take several years for reaching the commercial stage. Estimating the sales potential for CRISPR therapy is extremely difficult as it is highly prone to market conditions, pricing structures adopted by the companies, and broader acceptance by doctors and patients.

CRISPR Therapy 2017 last edit: 2017-12-13T18:02:15+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar